The few primary stroke treatments, including tissue-type plasminogen activator (tPA) or endovascular interventions, must be given in short-time windows and possess high risks (Kaesmacher et al., 2017; Lees et al., 2010). This evidence concerns the gene PLAT and stroke disorder.